Left ventricular mass-to-strain ratio to predict treatment response and prognosis in hypertensive heart disease

In-Chang Hwang; Hyue Mee Kim; Jiesuck Park; Hong-Mi Choi; Yeonyee E. Yoon; Goo-Yeong Cho

doi:10.1101/2025.02.25.25322843

Abstract

Background Typical hypertensive heart disease (HHD) phenotype is the left ventricular hypertrophy (LVH) and dysfunction, measurable via LV global longitudinal strain. We aimed to evaluate the LV mass-to-strain ratio (LV-MSR) as a marker of HHD treatment response and prognosis.

Methods We retrospectively analyzed consecutive patients who underwent echocardiography at hypertension diagnosis and 6–18-monthly intervals in tertiary centers from 2006–2021. Association between LV-MSR and LV geometry changes was assessed using receiver operating characteristic (ROC) analysis and multivariable logistic regression. Time-dependent ROC and Cox regression were performed to evaluate LV-MSR prognostic value for cardiovascular death and heart failure hospitalization.

Results Among 1,600 patients (mean age, 65.1 years; 61.1% male), 23.4% had concentric LVH, and 21.5% eccentric LVH at baseline. LV-MSR had the highest predictive accuracy for LV geometry changes (area-under-the-curve 0.786; 95% confidence interval [CI] 0.759– 0.813). LV-MSR showed significant association with new-onset LVH among the non-LVH group (adjusted odds ratio, 1.125, 95%CI 1.054–1.200, P<0.001) and persistent LVH among LVH group (adjusted hazard ratio [aHR] 1.133, 95%CI 1.087–1.180, P<0.001) at baseline. Higher LV-MSR was an independent prognosticator, whether as a continuous (aHR 1.032 per +1 g/m²/%, 95%CI 1.015–1.049, P<0.001) or categorical variable (aHR 2.257 for LV-MSR ≥6.52 g/m²/%, 95%CI 1.463–3.480, P<0.001). The associations persisted in subgroup analyses according to the presence of LVH baseline.

Conclusions LV-MSR independently predicts LV geometry changes and clinical outcomes in HHD, serving as a superior prognostic marker compared to LV mass index or LV-GLS alone.

What is new?

LV mass-to-strain ratio (LV-MSR) integrates LV geometry (LVH) and LV longitudinal function (LV-GLS), providing a more comprehensive assessment of hypertensive heart disease (HHD) than either parameter alone.

What are the clinical implications?

Higher LV-MSR predicts LVH progression, persistence, and worse clinical outcomes, making it a useful marker for risk stratification and treatment response assessment in hypertension.

Research Perspective

Further studies should validate LV-MSR across diverse populations, integrate it into standard echocardiographic protocols, and evaluate its role in clinical decision-making and antihypertensive treatment guidance to improve patient outcomes.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Protocols

https://cris.nih.go.kr/cris/search/detailSearch.do?seq=23707&search_page=L

Funding Statement

This study did not receive any funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Institutional Review Board of Seoul National University Bundang Hospital (No. B-2206-762-102), and the Institutional Review Board of Chung-Ang University Hospital (No. 2205-014-19419) gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

Conflict of Interest: The authors declare no conflicts of interest.
Typo errors in the manuscript and tables were revised. Graphical Abstract was removed, because it had echocardiographic images from patients.

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Abbreviations

ACME: average causal mediation effect
ADE: average direct effect
AUC: area under the curve
BMI: body mass index
CI: confidence interval
HHF: hospitalization for heart failure
LAVI: left atrial volume index
LV: left ventricle
LVH: left ventricular hypertrophy
LV-MI: left ventricular mass index
LV-GLS: left ventricular global longitudinal strain
LV-MSR: left ventricular mass-to-strain ratio
ROC: receiver-operating characteristics
RWT: relative wall thickness

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.